ArticleOncology letters2025

Efficacy and safety of SABR/partial-SABR combined with axitinib and toripalimab in recurrent or metastatic renal cell carcinoma: Preliminary results from a prospective phase 2 trial.

Ke Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.